Opendata, web and dolomites
  1. home
  2. trasparenza
  3. open h2020
  4. delirium monitor

Delirium Monitor

Objective delirium detection with an innovative EEG-based spot monitor

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0
 Outcomes and results

 Delirium Monitor project word cloud

Explore the words cloud of the Delirium Monitor project. It provides you a very rough idea of what is the project "Delirium Monitor" about.

2016    start    brain    detection    market    monitored    grows    diabetes    risk    incidences    mount    equaling    frequency    medical    serious    day    decline    alone    disposable    noise    burden    prolonged    home    sometimes    employees    underdiagnosed    generates    showed    care    nursing    budget    length    intensive    times    decades    double    validation    millions    134    ce    delirium    society    clinical    40    utrecht    frightening    revenue    feasibility    impaired    detect    surgical    months    usa    aging    sme    sales    70    granted    2021    patent    patch    fatal    costly    biomarker    eeg    minute    reported    automated    despite    hallucinations    icu    umc    impairs    horrifying    mm    nl    total    healthcare    electrodes    electrode    outcome    million    stresses    first    customers    patients    elderly    discharge    specialized    stay    thereafter    commercialize    2017    license    certification    world    create    unmet    yearly    recording    hospital    acute    cognitive    functioning    engineering    undertreated    billion    dementia    commit    device    80    rate    hospitalized   

Project "Delirium Monitor" data sheet

The following table provides information about the project.

Coordinator		 WILLEMS-TJOE NIJ ANNEMARIE CHRISTINE 

Organization address
address: FRED PETTERBAAN 21
city: AMSTERDAM
postcode: 1019 JT
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.
 Coordinator Country Netherlands [NL]
 Project website http://www.prolira.com
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SMEINST-1-2014
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-05-01   to  2015-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    WILLEMS-TJOE NIJ ANNEMARIE CHRISTINE NL (AMSTERDAM) coordinator 50˙000.00

Map

 Project objective

Delirium –an acute decline in cognitive functioning– is common, serious, frightening, costly and sometimes fatal. Delirium is a great burden for patients because of horrifying hallucinations and impaired outcome and increased risk on dementia. Delirium stresses society because of increased healthcare costs. This is due to prolonged length of hospital stay, and increased rate of discharge to a nursing home thereafter. Costs due to delirium total to €134 billion/year in Europe alone, equaling costs associated with diabetes. Delirium particularly affects hospitalized elderly with reported incidences of 50-80% on the Intensive Care Unit (ICU), and 10-40% in surgical patients. Because of our aging society, patients at risk for delirium will double in the next decades. Despite its frequency and impact, delirium remains underdiagnosed and therefore undertreated. Delirium is not recognized in 50 - 70% of the cases, which impairs outcome. Early and objective detection of delirium is an unmet clinical need. Mount Medical (MM), an SME specialized in medical devices, will create and commercialize the world’s first biomarker based device to detect delirium. UMC Utrecht (NL) showed that 1 minute recording of brain activity (EEG) with only 3 electrodes and automated processing could very well identify patients with delirium. A license on the patent will be granted to MM. Yearly, millions of patients are at risk of delirium that need to be monitored 3 times per day. This generates a €1.4 billion market in the EU and the USA, as for every measurement, a disposable electrode patch is necessary. A 6 months Phase 1 budget enables biomarker validation and development of noise reduction technology to show technical feasibility, and to commit customers into an Early Access program for market feasibility. Phase 2 is for product engineering and CE certification. EU sales start in 2016, and USA sales in 2017. MM grows to €10 million in revenue and 50 employees in 2021.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DELIRIUM MONITOR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DELIRIUM MONITOR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More